{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:08:12Z","timestamp":1793660892790,"version":"4.5.1"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"KBP Biosciences"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,4,21]]},"abstract":"<jats:p>KBP-7072 is a novel third-generation tetracycline (aminomethylcycline) antibacterial that overcomes common efflux and ribosomal protection resistance mechanisms that cause resistance in older-generation tetracyclines. KBP-7072 completed phase 1 clinical development studies for safety, tolerability, and pharmacokinetics (ClinicalTrials.gov identifier NCT02454361) and multiple ascending doses in healthy subjects (ClinicalTrials.gov identifier NCT02654626) in December 2015. Both oral and intravenous formulations of KBP-7072 are being developed.<\/jats:p>","DOI":"10.1128\/aac.02375-19","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T13:31:43Z","timestamp":1581514303000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["<i>In Vitro<\/i>\n            Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates"],"prefix":"10.1128","volume":"64","author":[{"given":"Michael D.","family":"Huband","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"University of Iowa, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Lindley","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Strand","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent J.","family":"Benn","sequence":"additional","affiliation":[{"name":"KBP Biosciences USA, Inc., Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Zhang","sequence":"additional","affiliation":[{"name":"KBP Biosciences USA, Inc., Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"KBP Biosciences Co., Ltd., Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"KBP Biosciences Co., Ltd., Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Tan","sequence":"additional","affiliation":[{"name":"KBP Biosciences Co., Ltd., Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmei","family":"Liu","sequence":"additional","affiliation":[{"name":"KBP Biosciences Co., Ltd., Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/367622"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1368-7646(02)00051-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025387"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4892(01)00081-9"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02404-18"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Kaminishi T Schedlbauer A Ochoa-Lizarralde B de Astigarraga E \u00c7apuni R Yang F Benn V Liu Q Tan X Zhang M Connell SR Fucini P. 2018. The third-generation tetracycline KBP-7072 exploits and reveals a new potential of the primary tetracycline binding pocket. bioRxiv 508218. https:\/\/doi.org\/10.1101\/508218.","DOI":"10.1101\/508218"},{"key":"e_1_3_2_8_2","unstructured":"Wang Y Liu Q Zhang B. 2016. Antibacterial activity of KBP-7072 against clinical isolates of drug-resistant bacteria abstr Monday-565. Abstr ASM Microbe 2016 16 to 20 June 2016 Boston MA."},{"key":"e_1_3_2_9_2","volume-title":"Safety, tolerability and pharmacokinetics of KBP-7072","author":"ClinicalTrials.gov","year":"2015","unstructured":"ClinicalTrials.gov. 2015. Safety, tolerability and pharmacokinetics of KBP-7072. National Library of Medicine, Bethesda, MD. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02454361?cond=kBP-7072&draw=2&rank=1."},{"key":"e_1_3_2_10_2","volume-title":"A multiple ascending dose study of KBP-7072 in healthy subjects","author":"ClinicalTrials.gov","year":"2015","unstructured":"ClinicalTrials.gov. 2015. A multiple ascending dose study of KBP-7072 in healthy subjects. National Library of Medicine, Bethesda, MD. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02654626?cond=kBP-7072&draw=2&rank=2."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.03.014"},{"key":"e_1_3_2_13_2","volume-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","author":"WHO","year":"2017","unstructured":"WHO. 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO, Geneva, Switzerland. http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3957-c1"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0267-8"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy293"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.10.007"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00159-19"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04809-14"},{"key":"e_1_3_2_21_2","unstructured":"Hwang S Efimova E Fyfe C Hawser S Morrissey I. 2019. Global in vitro surveillance of eravacycline against Gram-negative and Gram-positive clinical isolates including multidrug-resistant pathogens collected in 2017 abstr Friday-543. ASM Microbe 20 to 24 June 2019 San Francisco CA."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.02.017"},{"key":"e_1_3_2_23_2","volume-title":"M100Ed29","author":"CLSI","year":"2019","unstructured":"CLSI. 2019. Performance standards for antimicrobial susceptibility testing: 29th informational supplement. M100Ed29. CLSI, Wayne, PA."},{"key":"e_1_3_2_24_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. CLSI, Wayne, PA.","edition":"11"},{"key":"e_1_3_2_25_2","unstructured":"EUCAST. 2019. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0 January 2019. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_2_26_2","volume-title":"US FDA-recognized antimicrobial susceptibility test interpretive criteria","author":"FDA","year":"2019","unstructured":"FDA. 2019. US FDA-recognized antimicrobial susceptibility test interpretive criteria. FDA, Silver Spring, MD. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm410971.htm."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02375-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02375-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:45:28Z","timestamp":1645479928000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02375-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4,21]]}},"alternative-id":["10.1128\/AAC.02375-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02375-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"2019-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02375-19"}}